BACTROBAN CREAM
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
11-02-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
MUPIROCIN (MUPIROCIN CALCIUM)
Tillgänglig från:
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
ATC-kod:
D06AX09
INN (International namn):
MUPIROCIN
Dos:
2%
Läkemedelsform:
CREAM
Sammansättning:
MUPIROCIN (MUPIROCIN CALCIUM) 2%
Administreringssätt:
TOPICAL
Enheter i paketet:
15G
Receptbelagda typ:
OTC
Terapiområde:
ANTIBIOTICS
Produktsammanfattning:
Active ingredient group (AIG) number: 0117081001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2020-07-24
Produktens egenskaper
_ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
BACTROBAN
® CREAM
Mupirocin Cream USP 2% (w/w) as mupirocin calcium
TOPICAL ANTIBIOTIC
GlaxoSmithKline Consumer Healthcare Inc
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Date of Preparation:
July 6, 2016
Submission Control No: 194464
® Bactroban is a registered trademark, used under license by
GlaxoSmithKline Consumer Healthcare Inc.
_ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................10
SPECIAL HANDLING INSTRUCTIONS
.......................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEU
Läs hela dokumentet
